Quantcast

Latest Panitumumab Stories

2011-07-27 07:35:00

QUEBEC CITY, July 27, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the completion of patient recruitment for the ongoing Phase 3 trial with perifosine in refractory advanced colorectal cancer. The trial, involving over 430 patients, is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) and with Fast Track Designation. It is sponsored by Keryx Biopharmaceuticals, Inc.,...

2011-07-27 07:30:00

NEW YORK, July 27, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced completion of patient enrollment in its Phase 3 registration trial of KRX-0401 (perifosine) for the treatment of refractory, advanced colorectal cancer. This Phase 3 trial, with over 430 randomized patients, is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) and with Fast-Track Designation. Perifosine is a novel, potentially...

2011-06-24 09:59:00

THOUSAND OAKS, Calif., June 24, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Vectibix® (panitumumab) be approved for use in the European Union (EU) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy...

2011-05-26 09:14:00

OMAHA, Neb., May 26, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) announced today that it has acquired an exclusive worldwide license to Montefiore Medical Center's (Bronx, NY, US) patent application, "Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including cetuximab, panitumumab and erlotinib". The invention relates to the discovery by Montefiore scientists and collaborators that tumor-specific mutations in the genes PIK3CA and PTEN can aid in...

2011-05-18 17:05:00

THOUSAND OAKS, Calif., May 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from studies involving nine Amgen products will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3 - 7, 2011 in Chicago. These studies include data from the XGEVA® (denosumab), Vectibix® (panitumumab), ganitumab (AMG 479) and AMG 386 programs. "Amgen researchers around the globe are passionate about developing new...

2011-05-11 19:40:21

Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor (EGFR), and found that a decoy receptor might be limiting the amount of drug that gets to the intended target. "We know that smart drugs like Cetuximab are not always effective in the cancer cells...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related